Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...

Panelists discuss how JAK inhibitor therapy, while effective in treating myelofibrosis and other hematologic disorders, increases the risk of skin cancers, particularly non-melanoma skin cancers, and ...

Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

Alopecia universalis (AU) is a rare autoimmune condition that involves complete loss of hair on your face, scalp, and body.

Join Drs Tania Jain and Prithviraj Bose as they discuss the available JAK inhibitors and how they use them to treat ...

Janus kinase inhibitors (JAKis) are emerging as promising agents for improving skin repigmentation in people with vitiligo, according to a new systematic review and meta-analysis evaluating their ...

A recent cross-sectional study explored which clinical and disease-related factors are independently associated with VTE in RA, uncovering several notable associations, including a strong link with ...

AbbVie’s Rinvoq is now the first and only oral Janus kinase (JAK) inhibitor to be approved in the US for adults with GCA, and could allow patients to taper off steroids. “This FDA approval will now ...